Literature DB >> 11035344

Low-dose folic acid supplementation reduces plasma levels of the cardiovascular risk factor homocysteine in postmenopausal women.

V De Leo1, A La Marca, G Morgante, F Ciani, E Zammarchi, C Setacci.   

Abstract

OBJECTIVE: The aim of our randomized, controlled trial was to verify the effect of folic acid supplementation on homocysteine levels in postmenopausal women. STUDY
DESIGN: Thirty-six women were divided randomly into 2 groups as follows: a placebo group (n = 18) and a group receiving 500 microg folic acid per day for 4 weeks (n = 18). To assess concentrations of plasma homocysteine, venous blood samples were taken on enrollment and after 4 weeks of treatment.
RESULTS: Mean plasma homocysteine levels were 10.9 +/- 2.7 micromol/L in the placebo group and 7.8 +/- 2.35 micromol/L (P <.01) in the group receiving 500 microg folic acid per day for 4 weeks. The thirds (referred to as tertiles) of women with the highest baseline homocysteine plasma levels showed the greatest reduction in homocysteine, with a mean decrease of 4.35 micromol/L (32%; P <.01), in comparison with a decrease of 3.35 micromol/L (29%; P <.01) in the middle tertile and 1.3 micromol/L (22.4%; P =.09) in the lower tertile.
CONCLUSIONS: The results show that low doses of folic acid are associated with a significant reduction in plasma concentrations of homocysteine. The highest initial levels of homocysteine showed the most important reduction after therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035344     DOI: 10.1067/mob.2000.106345

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  1 in total

Review 1.  Hyperhomocysteinemia as a Risk Factor and Potential Nutraceutical Target for Certain Pathologies.

Authors:  Caterina Tinelli; Antonella Di Pino; Elena Ficulle; Serena Marcelli; Marco Feligioni
Journal:  Front Nutr       Date:  2019-04-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.